Verve Therapeutics, Inc. (NASDAQ:VERV) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Verve Therapeutics will make substantially more sales than they'd previously expected. Investors have been pretty optimistic on Verve Therapeutics too, with the stock up 37% to US$17.96 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.

After the upgrade, the consensus from Verve Therapeutics' nine analysts is for revenues of US$10m in 2024, which would reflect a definite 12% decline in sales compared to the last year of performance. Losses are supposed to balloon 29% to US$3.09 per share. However, before this estimates update, the consensus had been expecting revenues of US$9.3m and US$3.40 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

Check out our latest analysis for Verve Therapeutics

It will come as no surprise to learn that the analysts have increased their price target for Verve Therapeutics 5.1% to US$48.25 on the back of these upgrades.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 12% annualised revenue decline to the end of 2024. That is a notable change from historical growth of 134% over the last three years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 18% annually for the foreseeable future. It's pretty clear that Verve Therapeutics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Verve Therapeutics is moving incrementally towards profitability. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. There was also an increase in the price target, suggesting that there is more optimism baked into the forecasts than there was previously. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Verve Therapeutics.